ArticleInternational journal of clinical and experimental medicine2015
PIAS3, an inhibitor of STAT3, has intensively negative association with the survival of gastric cancer.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Insights into SUMOylation in gastric cancer: molecular mechanisms and emerging therapeutic opportunities.Journal of cancer research and clinical oncology · 2025Review
- SUMO Proteomics Analyses Identify Protein Inhibitor of Activated STAT-Mediated Regulatory Networks Involved in Cell Cycle and Cell Proliferation.Journal of proteome research · 2023Article
- The Expression and Prognostic Value of SUMO1-Activating Enzyme Subunit 1 and Its Potential Mechanism in Triple-Negative Breast Cancer.Frontiers in cell and developmental biology · 2021Article
- Overexpressed circPVT1 in oral squamous cell carcinoma promotes proliferation by serving as a miRNA sponge.Molecular medicine reports · 2019Article
- The PIAS3-Smurf2 sumoylation pathway suppresses breast cancer organoid invasiveness.Oncotarget · 2017Article
- The long noncoding RNA CASC2 functions as a competing endogenous RNA by sponging miR-18a in colorectal cancer.Scientific reports · 2016Article
- The SUMO (Small Ubiquitin-like Modifier) Ligase PIAS3 Primes ATR for Checkpoint Activation.The Journal of biological chemistry · 2016Article
- SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer.Trends in biochemical sciences · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe present study was conducted to elucidate the prognostic prediction value of the expression of the protein inhibitor of activated signal transducer and activators of transcription 3 (PIAS3) in gastric cancer (GC).
methodsWe detected the expression of PIAS3 in GC tissue, adjacent non-tumor tissue, GC cell lines, and GES-1 cell line. Besides, both clinicopathological data and follow-up records were obtained for patients' survival analyses.
resultsWe showed that both protein and mRNA expression of PIAS3 in GC tissue were significantly lower than those in adjacent non-tumor tissue, respectively. Besides, the relative mRNA expression value of PIAS3 in each of GC cell lines was also much lower than that in GES-1 cell line. With multivariate survival analyses, PIAS3 protein expression in GC tissues, and status of lymph node metastasis were identified to be the independently prognostic predictors of GC by using the Cox regression with bootstrapping method.
conclusionsLower expression of PIAS3 protein, indicating the poor survival of GC, is a potential marker for prediction the prognosis of patients.
Indexed as
Identifiers
25785044PMC4358499W2417079398What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.